Mohammed Alghamdi

Mohammed Alghamdi

Auto-generated profile, based on publicly available information

Mohammed Alghamdi

Department of Medical Oncology, King Saud University Medical City, King Saud University, National Blood and Cancer Centre, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in JCO Global Oncology
Verified
Journal Article
Open access
SBShouki Bazarbashi
Shouki Bazarbashi
RARadwan Alkhatib
Radwan Alkhatib
MAMohamed Aseafan
Mohamed Aseafan
YTYasmin Tuleimat
Yasmin Tuleimat
NANashwa Abdel-Aziz
Nashwa Abdel-Aziz
MAMohammed Alghamdi
Mohammed Alghamdi
PURPOSE: Metastatic colorectal cancer (mCRC) is a significant global health burden. This retrospective study compared the effectiveness of trifluridine/tipiracil (FTD/TPI), regorafenib, and chemotherapy rechallenge for third-line mCRC treatment. MATERIALS AND METHODS: We reviewed the medical records of 132 patients with mCRC treated with regorafenib, FTD/TPI, or a rechallenge with the initial chemotherapy regimen in a third-line setting from four different institutions. The primary end point was progression-free survival (PFS). Secondary end points were objective response rate and overall survival (OS) across the three treatment approaches. RESULTS: Twenty-nine patients received chemotherapy rechallenge, and 103 received FTD/TPI or regorafenib. Patients' characteristics were comparable, except for a lower number of left-sided primaries and KRAS wild-type tumors in the FTD/TPI-regorafenib group. The median PFS for the entire group was 3.0 months, and the median OS was 13.7 months. Chemotherapy rechallenge has resulted in a median PFS of 3.1 months and a median OS of 21.2 months, compared with 2.9 months (PFS) and 12.6 months (OS) for the FTD/TPI-regorafenib group. Multivariate analyses identified male sex and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 as independent prognostic factors for better PFS, whereas chemotherapy rechallenge, localized stage at diagnosis, and an ECOG PS of 0-1 were significant prognostic factors for better OS. CONCLUSION: This study suggests that chemotherapy rechallenge may provide a survival benefit in the third-line treatment of mCRC. However, patient characteristics, such as sex and ECOG PS, should also be considered in treatment decisions. Further prospective studies are required to confirm our findings.

18 July 2026 in eClinicalMedicine
Verified
Journal Article
Open access
EAEman A. Alghamdi
Eman A. Alghamdi
NANouf S. Alfadel
Nouf S. Alfadel
AAAhlam A. Alghamdi
Ahlam A. Alghamdi
BABasmah A. Albabtain
Basmah A. Albabtain
MAMuneerah M. Aleissa
Muneerah M. Aleissa
FAFawaz F. Alharbi
Fawaz F. Alharbi